drugset / Trial / NCT03180333

The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

NCT03180333

Phase 1 Completed 16 enrolled Guangzhou Yipinhong Pharmaceutical CO.,LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

Conduct in Chinese healthy adult subjects:1.To observe the safety and tolerability of multiple-dose oral administration of different doses of PNA;2.By measuring the changing drug concentration in the plasma and urine after a single oral administration of different doses of PNA on the condition of fasting, the pharmacokinetic parameters of the single dose are estimated;3.By measuring the changing drug concentration in the plasma of PNA after a multiple-dose oral administration on the condition of fasting, the pharmacokinetic parameters of multiple-dose are estimated, and a basis for dosage regimens of the clinical research phase Ⅱ is provided;4.To study the effects of diet on the pharmacokinetic parameters via the changes of concentration of PNA in plasma after high-fat and high-calorie food.

Timeline

Start
2012-03
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Metacavir Small molecule 80 mg Oral
Subject Metacavir Small molecule 160 mg Oral
Subject Metacavir Small molecule 320 mg Oral